New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 13, 2012
10:12 EDTFBHS, CPRT, BKD, OIS, DRC, BEAV, GRA, SNTA, NX, BKW, MCP, MDCA, BWLD, EAT, AYR, ACGL, ADK, AXSOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AXIS Capital (AXS) initiated with a Buy at Goldman... AdCare (ADK) initiated with an Outperform at Imperial Capital... Aircastle (AYR) initiated with a Buy at Deutsche Bank... Albermarle (ALB) initiated with an Outperform at RW Baird... Arch Capital (ACGL) initiated with a Neutral at Goldman... Brinker (EAT) initiated with a Buy at Citigroup... Buffalo Wild Wings (BWLD) initiated with a Neutral at Citigroup... Burger King (BKW) initiated with a Buy at Citigroup... MDC Partners (MDCA) initiated with a Buy at Capstone... Molycorp (MCP) initiated with a Neutral at RW Baird... Quanex (NX) initiated with an In-Line at Imperial Capital... Synta Pharmaceuticals (SNTA) initiated with a Buy at Brean Capital... W.R. Grace (GRA) initiated with an Outperform at RW Baird... BE Aerospace (BEAV)initiated with an Overweight at JPMorgan... Fortune Brands (FBHS) initiated with a Neutral at JPMorgan... Dresser-Rand (DRC) initiated with a Buy at Guggenheim... Oil States (OIS) initiated with a Buy at Guggenheim... Brookdale Senior Living (BKD) initiated with a Neutral at Macquarie... Copart (CPRT) initiated with a Buy at Northcoast.
News For AXS;ADK;ACGL;AYR;EAT;BWLD;MDCA;MCP;BKW;NX;SNTA;GRA;BEAV;DRC;OIS;BKD;CPRT;FBHS From The Last 14 Days
Check below for free stories on AXS;ADK;ACGL;AYR;EAT;BWLD;MDCA;MCP;BKW;NX;SNTA;GRA;BEAV;DRC;OIS;BKD;CPRT;FBHS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 22, 2014
15:30 EDTBEAVNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include PepsiCo (PEP) , consensus $1.23; Boeing (BA), consensus $2.01; Dow Chemical (DOW), consensus 72c; EMC (EMC), consensus 43c; Simon Property Group (SPG), consensus $2.13; Thermo Fisher (TMO), consensus $1.62; General Dynamics (GD), consensus $1.77; Freeport-McMoRan (FCX), consensus 49c; Delta Air Lines (DAL), consensus $1.04; Northrop Grumman (NOC), consensus $2.22; Whirlpool (WHR), consensus $2.91; B/E Aerospace (BEAV), consensus $1.07; Ryder (R), consensus $1.40; Owens Corning (OC), consensus 46c.
10:01 EDTSNTASynta Pharmaceuticals strength a selling opportunity, says Stifel
Subscribe for More Information
09:07 EDTSNTASynta Pharmaceuticals data positive, says JMP Securities
JMP Securities believes that early top-line data indicates Synta's ganetespib plus current standard of care, low-dose Ara-C provide clinical benefit in high-risk elderly patients with newly diagnosed AML and MDS. The firm says the results increase its confidence in a positive GALAXY-2 outcome in NSCLC and broad applicability of ganetespib across a variety of tumor types. It keeps an Outperform rating on the stock.
06:43 EDTBKWChina food scandal expands, ropes-in Starbucks, others, Reuters says
Subscribe for More Information
July 21, 2014
16:32 EDTSNTASynta Pharmaceuticals advances ganetespib into Phase 3 extension of AML LI-1
Synta Pharmaceuticals announced the advancement of ganetespib into the Phase 3 extension of the AML LI-1 trial. AML LI-1 is a multicenter, randomized Phase 2/3 clinical study evaluating several novel treatment regimens, including the combination of ganetespib with low dose cytarabine, in newly diagnosed elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome who are not eligible for intensive chemotherapy. Ganetespib is a next-generation inhibitor of the chaperone protein Hsp90, which is critical for the activation and stability of numerous proteins that drive cancer growth and proliferation. Ganetespib has been studied in over 1000 patients to date. Advancement into the Phase 3 extension follows an interim analysis of results from 50 patients who received the ganetespib-cytarabine combination in the Phase 2 portion of the trial. The primary efficacy outcome in Phase 2 was rate of complete response. Per protocol, the Phase 3 extension will include an interim futility analysis and enroll approximately 200 patients in the ganetespib-cytarabine and the cytarabine alone arms, for a total of approximately 400 patients. The primary efficacy endpoint for the Phase 3 extension will include overall survival. The Company is currently in discussion with study investigators, and anticipates providing additional details, including the timing of study milestones, as they become formalized. The AML LI-1 trial is the first of three multicenter, randomized studies supported by the Leukemia & Lymphoma Research Fund and Cancer Research UK to include a ganetespib treatment arm. AML LI-1 is being conducted under the auspices of the UKs National Cancer Research Institute Haematological Oncology Study Group, with investigators in Denmark, France, New Zealand, and the UK, and under the sponsorship of Cardiff University, UK. The other two studies, to be initiated later this year, are the AML-18 trial, evaluating ganetespib with standard DA in patients over 60 years old who can tolerate intensive chemotherapy, and the AML-19 trial, evaluating ganetespib in combination with conventional chemotherapy in younger patients with AML.
05:54 EDTMCPStocks with implied volatility movement; MPEL MCP
Subscribe for More Information
July 20, 2014
12:07 EDTCPRTCopart shares could climb 20%, Barron's says
Subscribe for More Information
July 18, 2014
09:14 EDTDRCGE says not done with divestitures, likes current Oil & Gas portfolio
Subscribe for More Information
July 17, 2014
16:52 EDTDRCOn The Fly: Closing Wrap
Subscribe for More Information
14:09 EDTDRCDresser-Rand takeover unlikely, sayd Raymond James
Raymond James said a takeover of Dresser-Rand is unlikely unless the stock price is meaningfully higher.
13:18 EDTDRCOn The Fly: Midday Wrap
Subscribe for More Information
09:15 EDTOIS, DRCOn The Fly: Pre-market Movers
HIGHER: Dresser-Rand (DRC), up 15.5% after Manager Magazin says Siemens (SIEGY) preparing bid for the company. Other oil equipment companies with a market cap similar to Dresser-Rand's include Dril-Quip (DRQ) and Oil States (OIS)... Microsoft (MSFT), up 3.4% after announcing restructuring, including plans to cut up to 18K jobs. UP AFTER EARNINGS: Morgan Stanley (MS) up 1.5%... Sherwin-Williams (SHW), up 3%. DOWN AFTER EARNINGS: Mattel (MAT), down 7.3%... Sandisk (SNDK), down 7%... Yum! Brands (YUM), down 2.5%. LOWER: Orbitz (OWW), down 3% after results, 34M share spot secondary offering of stock priced at $8.25... Benefitfocus (BNFT), down 1% after 2.5M share Secondary priced at $38.50.
09:05 EDTBKWCarrols Restaurant purchases 21 Burger King restaurants
Subscribe for More Information
07:08 EDTDRCDresser-Rand volatility expected to move on Siemens preparing bid report
Dresser-Rand (DRC) volatility is expected to move Siemens (SIEGY) is working with Lazard on a takeover bid for Dresser-Rand (DRC), Germany's Manager Magazin reports, citing sources. Overall option implied volatility of 25 is at its 26-week average according to Track Data, suggesting non-directional price movement.
06:27 EDTAXSPlatinum Q2 may turn reinsurance sentiment negative, says Citigroup
Subscribe for More Information
06:17 EDTDRCSiemens preparing bid for Dresser-Rand, Manager Magazin says
Siemens (SIEGY) is working with Lazard on a takeover bid for Dresser-Rand (DRC), Germany's Manager Magazin reports, citing sources close to Siemens. The German multinational would consider a hostile approach should Dresser-Rand rebuff its advances, the report adds. Shares Dresser-Rand, which manufactures a wide variety of products for use in the oil, gas, and process industries, closed yesterday up 12c to $60.42. The company has a market capitalization of $4.62B. Reference Link
05:59 EDTMCPMolycorp implied volatility of 115 at upper end of index mean range
July 16, 2014
10:00 EDTOIS, BKD, DRCOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: American Airlines (AAL) initiated with an Overweight at Atlantic Equities... Apple (AAPL) initiated with a Buy at Citigroup... Basic Energy (BAS) initiated with a Neutral at RW Baird... Brookdale Senior Living (BKD) initiated with a Buy at Goldman... CA Technologies (CA) initiated with a Market Perform at FBR Capital... Dresser-Rand (DRC) initiated with a Neutral at RW Baird... Fortinet (FTNT) initiated with a Neutral at Goldman... Frank's International (FI) initiated with a Hold at Jefferies... Home Bancorp (HBCP) initiated with an Outperform at Fig Partners... Key Energy (KEG) initiated with an Outperform at RW Baird... McDermott (MDR) initiated with a Neutral at Tigress Financial... ORBCOMM (ORBC) initiated with a Neutral at Macquarie... Oil States (OIS) initiated with an Outperform at RW Baird... PBF Energy (PBF) initiated with an Equal Weight at Barclays... Palo Alto (PANW) assumed with a Conviction Buy at Goldman... Proofpoint (PFPT) initiated with a Buy at Goldman... Qlik Technologies (QLIK) initiated with a Market Perform at FBR Capital... Radius Health (RDUS) initiated with a Buy at Canaccord... Seventy Seven Energy (SSE) initiated with a Hold at Jefferies... Superior Energy (SPN) initiated with an Outperform at RW Baird... Tandem Diabetes (TNDM) initiated with an Outperform at William Blair... Trecora Resources (TREC) initiated with a Buy at B. Riley... Ultragenyx (RARE) initiated with an Outperform at RW Baird... United Natural Foods (UNFI) initiated with an Outperform at Oppenheimer... Viper Energy (VNOM) initiated with a Market Perform at Northland... Whiting Petroleum (WLL) initiated with a Buy at Tigress Financial.
08:21 EDTGRAW.R. Grace weakness creates buying opportunity, says KeyBanc
KayBanc believes that W.R. Grace's underperformance since emerging from bankruptcy has created a buying opportunity. The firm expects the company's EPs growth to accelerate to double digit percentage levels in 2H14. The firm thinks the company could report stronger than expected Q2 results.
05:53 EDTBKDBrookdale Senior Living initiated with a Buy at Goldman
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use